Screening and Diagnosis of Hepatitis C infection in Hemodialysis Patients

Mervat Abd-Elminein¹, Mohamed Ali Abd El-Baseer², Mona Abd-gelel Mohamed³, and Omyma Mohamed Elmahalowy⁴

Biochemistry Department, faculty of medicine for girls, Al-azar university¹, Microbiology and botany Department, faculty of science for boys², Al-azar university Biochemistry Division, Chemistry Department, faculty of sciences for girls³, Researcher in Al-Azhar university center for virus research and studies, faculty of medicine for girls ⁴

Abstract

Study was done on Egyptian hemodialysis patient of detection of hepatitis B surface antigen (HBsAg), antibody to human immunodeficiency virus type and type 2(anti-HIV1/2) and hepatitis C antibody (anti-HCV). HCV antibodies are insensitive in the acute phase because of the long serological window. Direct detection of HCV depends on PCR test but this test is not suitable for routine screening. Recombinant immunoblot assays are used as supplemental tests. The results from 200 individuals 120 males (60%) and 80 females (40 %) in the eight dialysis centers in Egypt were analyzed in this study. All patients were negative for antibodies to HIV and HBsAg. Hepatitis C antibody (anti-HCV) 100 patients were negative HCVAb (50%), 70 pateints positive HCVAb (35%), 30 patients were in grey zone (15%) Twenty patients from 100 negative HCVAb as control group were confirmed by HCVRNA (PCR), 7 were positive (35%) and 13(65%) were negative. The grey zone 30 patients showed 2 (6.7%)negative and 28(93.3%) positive HCVRNA. Thirty Patients from 70 positve anti-l 1CV showed one (3.3%)negative and 29 (96.7%) positive HCV-RNA.

Introduction

HCV infection is a major public health problem with an estimated global prevalence of HC 4%. There are about 180 million chronic carriers and approximately 4 million people annually are newly infected. (Soin et al., 2015). Hepatitis C virus (HCV) is a single-stranded positive sense RNA virus with a genome of about 10,000 nucleotides containing a single large, continuous open reading frame and with an organization most closely resembling the family Flavviridae from genus hepacivirus (Lemon..et al 2007).

Hepatitis C virus (HCV) infection remains frequent in patient receiving long-term dialysis both in developed and less developed countries. Recent evidence indicates that HCV plays a detrimental effect on survival in the dialysis population, but it remains unknown whether the elevated mortality risk because of HCV infection is only attributable to an increase in liver disease-related deaths. (Fabrizi, et al., 2012).

The prevalence of HCV infection is much higher in patients on chronic hemodialysis (HD) than in the general population despite the control of blood products. Hepatitis C virus is a significant cause of morbidity and mortality in patients who is treated with dialysis (Etik et al., 2015). Virological diagnosis and monitoring of HCV infection
is based on two categories of laboratory tests, namely serologic assays detecting specific antibodies to HCV (anti-HCV) and assays that can detect, quantify or characterize the components of HCV viral particles such as HCV RNA. (Kesli et al., 2011).

Early stages of the infection are missed because the antibodies develop only after one and half months of infection and the tests for anti HCV antibody may be negative in the initial period before the seroconversion phase (Lai 2001). This window phase can be longer in hemodialysis patients as these patients are severely immunocompromised. In such situations, the HCV RNA detection by polymerase chain reaction (RT-PCR) is highly sensitive and is a reliable test in the early diagnosis of HCV infection. (Reddy et al., 2005). HCV infection is usually diagnosed based on the detection of anti-HCV antibody, while it goes undetected in the first 4-6 weeks of infection (so-called window period). Furthermore, patients positive for anti-HCV antibody include both those who are actively infected and those who have recovered from infection. (Perico et al., 2009)

Diagnostic procedures of hepatitis C virus infection in laboratories are principally based on the detection of antibodies (IgG) against recombinant HCV polypeptides by two main methods: Enzyme immunoassay (EIA) and Chemiluminescence immunoassay (CIA). Nonstructural and recombinant antigens have been used in the production of immunoassay reactives. Serologic and virologic markers of past or present HCV infection include IgG antibodies (anti-HCV). An assay for IgM anti-HCV is available, but it does not distinguish between acute and chronic HCV infection. (Ansari and, Omrani 2006). Three different generations of HCV kits have been developed to date. The first generation HCV enzyme immunoassay detected only antibodies against non-structural region 4 (NS4) with recombinant antigen cl00-3. First- generation anti-HCV reactive had relatively poor specify and sensitivity. In the development of second-generation tests, additional antigens from the core region (c22-3), the NS3 region (c33c) and a part of c 100-3 from the NS4 region were used. Second-generation reactive show increased sensitivity and specify. Third-generation EIA includes an additional antigen from the NS5 protein and a reconfiguration of the core and NS3 antigens. (Fiebelkorn, and Nolte 2004) and (Wu FB., et al., 2008). The newest generation of immunoassays available, that is, fourth generation of tests is those that simultaneously detect HCV capsid antigen as well as antibodies to the core, NS3, NS4, and NS5 regions of the virus (Gupta et al., 2014).

**Patient and Methods**

Two hundred patients (20 to 74 years) suffering from renal failure and undergoing hemodialysis were selected from different hemodialysis centers in Cairo, Egypt. Serum samples patient performed the routine hemodialysis 3 times/week three months ago were investigated in Al-Azhar University Center for Virus Research.

Blood samples were collected before dialysis and serum was obtained by centrifugation at 4°c for 10 min at 5000rpm. Serum samples were aliquot and stored at - 80°c. From the 200 patients, only 100 patients were HCV positive (30 were located at the grey zone). According to the results of ELISA HCV-Ab, patients were categorized into three groups:

**Group I:** 20 hemodialysis patients (11 males and 9 females) negative HCV-Ab (Control)

**Group II:** 30 hemodialysis patients (17 males and 13 females), who were suspected for HCV infection, since HCV-Ab test was located at the grey zone range (0.5-1.5).
Group III: 30 hemodialysis patients (16 males and 14 females) positive HCV-Ab (+HCV-Ab).

Methods

Serum samples were tested for HIV, and HBsAg using commercial kits (ELISA DSI-Italy). HCV was detected by both ELISA (Biokit,USA) and Reverse transcriptase-PCR using the commercial kits (Qiagen ,USA) for RNA extraction while TaqTM master mix by (Fermintas ,USA).The primer used for HCV- RNA amplifid was desiged according to EL-Awady et al ,(2006) .

A-outer primers:
Primer-l(P1): is 21st sense primer sequence.
5 ’AACTACTGTTCTTCACGCAGAA 3’
Primer-2(P2): is 22nd anti- sense primer sequence.
5’GGTGCACGGTCTACGAGACCTC 3’

B-Inner Primers:
Primer-3(P 3): is 18nt sense primer sequence.
5’GTGCAGCCTCCAGGACCC 3*
Primer-4(P4): is nt anti -sense primer sequence.
5’ACTCGGCTAGCAGTCTCGCG 3’

Table (1): Thermal cycling conditions were as following:

<table>
<thead>
<tr>
<th>Temperature (°C)</th>
<th>Time (min)</th>
<th>Cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>30:00</td>
<td>RT Step</td>
</tr>
<tr>
<td>95</td>
<td>15:00</td>
<td>Taq Activation</td>
</tr>
<tr>
<td>94 55 72</td>
<td>1:00 1:00 1:00</td>
<td>PCR (40 cycle)</td>
</tr>
<tr>
<td>75</td>
<td>10:00</td>
<td>Final Extension</td>
</tr>
<tr>
<td>4</td>
<td>HOLD</td>
<td></td>
</tr>
</tbody>
</table>

An amplicon of 171 base pair length was identified in positive HCV- RNA sample on 2% agarose gel (figure 1).

Results

Our study includes 120 males (60%) and 80 females (40 %)undergoing hemodialysis from eight dialysis centers in Egypt. In this study demonstrated all patients were negative for antibodies to HIV and HBs Ag. We detected 100 patients HCVAb-negative (50%), 70 HCVAb-positive Patients (35 %), 30 patients in grey zone (15%).

Table (2): Detection of Anti-HCV by ELISA Test:

<table>
<thead>
<tr>
<th>GROUPS</th>
<th>ELISA RESULTS HCV-AB</th>
</tr>
</thead>
<tbody>
<tr>
<td>NO. PATIENTS</td>
<td>%</td>
</tr>
<tr>
<td>NEGATIVE</td>
<td>100</td>
</tr>
<tr>
<td>POSITIVE</td>
<td>70</td>
</tr>
<tr>
<td>GREY ZONE</td>
<td>30</td>
</tr>
</tbody>
</table>

Figure (1): PCR product for HCV-RNA on agarose gel stained with ethidium bromide.

1 2 3 4 5 6 7 8 9 10 11 12

Lanell Marker, Lane 2,8: control, Lane 3-7: grey zone, Lane,9-12: anti-HCV anti-HCV +ve
Table (3): Distribution of HCV infection in hemodialysis (HD) patients within the studied groups using the two detecting tests.

<table>
<thead>
<tr>
<th>Test</th>
<th>Group I (control) (n=20)</th>
<th>Group II (Anti HCV grey zone) (n=30)</th>
<th>Group III (Anti HCV +ve) (11=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HCV Ab Number %</td>
<td>20 100%</td>
<td>Equivocal range</td>
<td>30 100%</td>
</tr>
<tr>
<td>PCR Number %</td>
<td>7 35%</td>
<td>13 65%</td>
<td>28 93.3%</td>
</tr>
</tbody>
</table>

Discussion

Moini, reported that the anti-HCV tests may fail to detected HCV infection inl.66% to 7.2% in patients of maintenance hemodialysis (MHD), because the immunocompromised status of these patients prevents them from having detectable anti-HCV antibodies. So necessary to detected HCV RNA by polymerase chain reaction (PCR) in anti-HCV negative patients who were at high risk of HCV transmission (Moini et al., 2013).

Antibody tests fail to identify HCV infected subjects before seroconversion or during the window period, when specific antibodies have not yet been produced or are in low titres. However, the virus continues to replicate and RNA can be detected in the plasma (Carreno et al., 2012), (Hussei et al., 2010) and (Ansari et al., 2006).

Wu FB et al., 2008, reported that window period may extend up to two months in immunocompetent subjects or as long as 6 to 12 months in immune deficient patients (Wu FB eta./.,2008). Patients on hemodialysis or immunocompromised patients infected with HCV produce fewer antibodies. Direct measurement of the HCV virus in the serum of the infected individual remains the gold standard in the diagnosis of HCV infection. HCV RNA is detectable in the serum within one to two weeks after the infection. Virological diagnosis and monitoring of HCV infection are based on the use of serologic assays detecting specific anti- HCV Ab (Bouvier-Alias et al., 2002). The anti-HCVAb test also does not distinguish the individuals who have resolved HCV infection from the patients with active/ongoing HCV infection (Kesli et al., 2011). The anti-HCV assay is simple, inexpensive and rapid as a screening test, but lacks detection sensitivity in the early window period of 45 to 68 days after infection (Florea et al., 2014).

In this study, the control group 20 patients negative in HCV-Ab were 7 (35%) cases positive HCV-RNA. From all number of grey zone (30 patients )2 patients were negative HCV-RNA (6.7%)and 28 HCV- RNA were positive (93.3%), one patient (3.3%) negative HCV-RNA and 29(96.7%) HCV-RNA positive were diagnosed from the 30 HCVAb- Positive groups.

This was in agreement with Gioacchino,eta/.,2012, Florea et al., 2014 which demonstrated that although third-generation HCV reactive are more sensitive and specific than older generation assays, they still have a high percentage of false positive reactions, so that it is mandatory to confirm every reactivity, especially with low titers by anti- HCV RNA assay .HCV RNA is the earliest marker of infection, and a direct indicator of ongoing viral replication. It appears 1 to 2 weeks after infection before any alterations in liver enzyme levels and appearance of anti-HCV antibodies can be detected. Molecular biology techniques are the most efficient tools for the identification of HCV strains, useful both
for diagnosis and for viral characterization studies.

The polymerase chain reaction (PCR) technique when used for HCV infection, allows the identification of the acute phase of the infection. This is very important, considering that anti-HCV Ab is not detected during this phase (Moreira et al., 2005). However, nucleic acid amplifications involve considerable technical skill, high costs and longer turn-around time and may lead to false positive results due to contamination; for these reasons, amplification methods are not suitable for wide spread use in most laboratories, especially in developing countries (Morota et al., 2009; Soliman et al., 2015). The incorporation of the viral envelope proteins could be an alternative for the development of more sensitive, new immunoenzymatic tests (Moreira et al., 2005) and (Yongjung P, eta/2010).

Therefore, the HCV Core-Ag assay is needed as a supplemental or pre-confirmatory test to pre-confirm anti-HCV results (Kesli et al., 2011). In the present study, the immunoenzymatic (anti-HCVAb) test fails to detect 35% of the HCV infected patients in control group as confirmed by the HCV RNA amplification tests, while in grey zone groups and positive group for anti-HCVAb test fails to detect 6.7 and 3.3%, respectively, of uninfected patients as confirmed by the HCV RNA amplification test.

Conclusion
The HCV RNA assay is a reliable method but needs technical skill and may also result in false positivity because of contamination, and it is time intensive and more expensive in developing countries.

From this study we found that detection of HCV using anti - HCV antibody have Positive results in patients who have been recovered also may have false negative results in patients in window phase and immune compromised patients especially hemodialysis patients so we recommended in this study to use other method as confirmatory as HCVcore-Ag as it's simple ELISA technique and cheap.

Reference


7- European Association for Study of Liver. (2014): EASL Clinical
Practice Guidelines: (2014) management of hepatitis C virus infection. J Hepatol; 60: 392-420


11- Gioacchino Li Cavoli, Carmela Zagarrigo, Onofrio Schillaci, 2012: Hepatitis C Virus Core Antigen Test in Monitoring of Dialysis Patients, Nephrology and Dialysis, ARNAS Civico and Di Cristina Hospital, Via Francesco Cilea 43, 90144


